Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 24 Lung Neoplasms 14 Carcinoma, Medullary 14 Neoplasm Metastasis 12 Neoplasms 10 Thyroid Neoplasms 8 Breast Neoplasms 8 Glioma 6 Prostatic Neoplasms 5 Glioblastoma 5 Squamous Cell Carcinoma of Head and Neck 4 Gliosarcoma 4 Colorectal Neoplasms 4 Brain Neoplasms 4 Pancreatic Neoplasms 3 Ovarian Neoplasms 3 Head and Neck Neoplasms 3 Carcinoma, Renal Cell 3 Adenocarcinoma 3 Urinary Bladder Neoplasms 2 Thyroid Cancer, Papillary 2 Stomach Neoplasms 2 Recurrence 2 Rectal Neoplasms 2 Pleural Effusion 2 Kidney Neoplasms 2 Familial medullary thyroid carcinoma 2 Fallopian Tube Neoplasms 2 Esophageal Neoplasms 2 Disease Progression 2

Interventions

Fulvestrant 18 Letrozole 10 Anastrozole 8 Capecitabine 5 palbociclib 4 olaparib 4 Paclitaxel 4 Goserelin 4 Docetaxel 4 pyrotinib 3 exemestane 3 Vinorelbine 3 Injections 3 Aromatase Inhibitors 3 trastuzumab deruxtecan 2 toripalimab 2 sacituzumab govitecan 2 ribociclib 2 eribulin 2 elacestrant 2 dalpiciclib 2 abemaciclib 2 Trastuzumab 2 Gonadotropin-Releasing Hormone 2 FCN-437c 2 Everolimus 2 Dasatinib 2 Alpelisib 2 Albumin-Bound Paclitaxel 2 AZD9833 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Breast Cancer × vandetanib × Clear all

NCT00494481 2016-09-30

E3 Breast Cancer Taxotere Combination

Sanofi

Phase 2 Completed

64 enrolled 7 charts

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡